Information Provided By: 
Fly News Breaks for September 20, 2017
XLRN, CELG
Sep 20, 2017 | 06:59 EDT
Commentary from partner Acceleron Pharma's (XLRN) R&D day indicates Celgene (CELG) will announce lots of data in 2018, Jefferies analyst Michael Yee tells investors in a research note. He sees Celgene shares "grinding higher" over the next few months and into 2018 ahead of three major Phase III datasets: GED-301 in Crohn's, Ozanimod in ulcerative colitis and partner Acceleron's luspatercept in beta-thalassemia. The analyst keeps a Buy rating on Celgene with a $160 price target.
News For CELG;XLRN From the Last 2 Days
There are no results for your query CELG;XLRN
